Prevalence of Comorbidities and Their Influence on Blood Pressure Goal Attainment in Geriatric Patients
dc.contributor.author | Bisognano, John D. | en_US |
dc.contributor.author | Townsend, Kevin A. | en_US |
dc.contributor.author | Skyles, Amy J. | en_US |
dc.contributor.author | Samuels, Kiela M. | en_US |
dc.date.accessioned | 2010-06-01T19:27:20Z | |
dc.date.available | 2010-06-01T19:27:20Z | |
dc.date.issued | 2007-01 | en_US |
dc.identifier.citation | Bisognano, John D . ; Townsend, Kevin A . ; Skyles, Amy J . ; Samuels, Kiela M . (2007). "Prevalence of Comorbidities and Their Influence on Blood Pressure Goal Attainment in Geriatric Patients." The American Journal of Geriatric Cardiology 16(1): 24-29. <http://hdl.handle.net/2027.42/72595> | en_US |
dc.identifier.issn | 1076-7460 | en_US |
dc.identifier.issn | 1751-715X | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/72595 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17215639&dopt=citation | en_US |
dc.format.extent | 586847 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Le Jacq | en_US |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.rights | 2007 Le Jacq | en_US |
dc.title | Prevalence of Comorbidities and Their Influence on Blood Pressure Goal Attainment in Geriatric Patients | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Geriatrics | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | the University of Michigan College of Pharmacy, Ann Arbor, MI; | en_US |
dc.contributor.affiliationum | the University of Michigan Health System, Ann Arbor, MI | en_US |
dc.contributor.affiliationother | From the Program in Heart Failure and Transplantation, Cardiac Rehabilitation, and Clinical Preventive Cardiology, University of Rochester, Rochester, NY; | en_US |
dc.contributor.affiliationother | Pfizer Inc, New York, NY; | en_US |
dc.identifier.pmid | 17215639 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/72595/1/j.1076-7460.2007.05543.x.pdf | |
dc.identifier.doi | 10.1111/j.1076-7460.2007.05543.x | en_US |
dc.identifier.source | The American Journal of Geriatric Cardiology | en_US |
dc.identifier.citedreference | 1 The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289: 2560 – 2572. | en_US |
dc.identifier.citedreference | Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey. 1988–1991. Hypertension. 1995; 25: 305 – 313. | en_US |
dc.identifier.citedreference | Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA. 2003; 290: 199 – 206. | en_US |
dc.identifier.citedreference | 4 US Census Bureau. The 65 Years and Older Population: 2000. Washington, DC: US Census Bureau; 2001. | en_US |
dc.identifier.citedreference | 5 Implications of the systolic hypertension in the elderly program. The Systolic Hypertension in the Elderly Program Cooperative Research Group. Hypertension. 1993; 21: 335 – 343. | en_US |
dc.identifier.citedreference | Franklin SS, Jacobs MJ, Wong ND, et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension. 2001; 37: 869 – 874. | en_US |
dc.identifier.citedreference | Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: data from the health examination surveys, 1960 to 1991. Hypertension. 1995; 26: 60 – 69. | en_US |
dc.identifier.citedreference | 8 National Center for Health Statistics. Health Promotion and Disease Prevention United States, 1990. Hyattsville, MD: Public Health Service; 1993: 33. Dept of Health and Human Services publication 93 – 1513. | en_US |
dc.identifier.citedreference | Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Prospective Studies Collaboration. Lancet. 2002; 360: 1903 – 1913. | en_US |
dc.identifier.citedreference | 10 The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [published corrections appear in JAMA. 2003;289:178 and JAMA. 2004;291:2196]. JAMA. 2002; 288: 2981 – 2997. | en_US |
dc.identifier.citedreference | Black HR, Elliott WJ, Neaton JN, et al, for the CONVINCE Research Group. Baseline characteristics and early blood pressure control in the CONVINCE Trial. Hypertension. 2001; 37: 12 – 18. | en_US |
dc.identifier.citedreference | Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA. 2002; 287: 1003 – 1010. | en_US |
dc.identifier.citedreference | Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet. 2000; 356: 1955 – 1964. | en_US |
dc.identifier.citedreference | 14 National Kidney Foundation Guideline. K/DOQI clinical practice guidelines for chronic kidney disease. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis. 2002; 39 ( suppl 2 ): S1 – S246. | en_US |
dc.identifier.citedreference | Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003; 289: 2073 – 2082. | en_US |
dc.identifier.citedreference | Yusuf S, Sleight P, Poque J, et al, for the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342: 145 – 153. | en_US |
dc.identifier.citedreference | Pitt B, Remme W, Zannad F, et al, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348: 1309 – 1321. | en_US |
dc.identifier.citedreference | 18 UK Prospective Diabetes Study Group. Efficacy of atenolol and captoril in reducing risk of marcrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998; 317: 713 – 720. | en_US |
dc.identifier.citedreference | Wright JT Jr, Agodoa L, Contreras G, et al. Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med. 2002; 162: 1636 – 1643. | en_US |
dc.identifier.citedreference | DahlÖf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002; 359: 995 – 1003. | en_US |
dc.identifier.citedreference | 21 The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997; 157: 2413 – 2446. | en_US |
dc.identifier.citedreference | 22 Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42: 1206 – 1252. | en_US |
dc.identifier.citedreference | Wannemacher AJ, Schepers GP, Townsend KA. Antihypertensive medication compliance in a Veterans Affairs Healthcare System. Ann Pharmacother. 2002; 36: 986 – 991. | en_US |
dc.identifier.citedreference | Degli Esposti ED, Sturani A, Di Martino M, et al. Long-term persistence with antihypertensive drugs in new patients. J Hum Hypertens. 2002; 16: 439 – 444. | en_US |
dc.identifier.citedreference | Staessen JA, Fagard R, Thijs L, et al, on behalf of the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997; 350: 757 – 764. | en_US |
dc.identifier.citedreference | Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA. 2005; 294: 466 – 472. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.